Trial Profile
A Prospective ,Observational,Cohort study evaluating the efficacy of Nabiximols for drug-resistant Multiple Sclerosis spasticity
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 May 2017
Price :
$35
*
At a glance
- Drugs Nabiximols (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- 28 Apr 2017 Results assessing efficacy of Nabiximols presented at the 69th Annual Meeting of the American Academy of Neurology.
- 21 Nov 2016 New trial record